Novaquest Capital Management
NovaQuest Capital Management is a life-science investment firm focused on late-stage biopharmaceutical and animal health opportunities. The firm provides tailored, structured and non-dilutive capital solutions (branded PRODUCT FINANCE™) to advance pivotal clinical trials, launch products, monetize royalties and support commercialization. NovaQuest emphasizes a One Health perspective and integrates ESG considerations into its investment decision-making.
Novaquest Capital Management
Raleigh, North Carolina, United States, North America
Services
PRODUCT FINANCE™ (late-stage product financing)
At-risk, non-dilutive financing designed to support late-stage product development and commercialization activities including pivotal trials, brand launches, licensing and asset acquisitions.
Animal Health Partnerships and Product Financing
Capital and expertise for animal health companies, including product financing agreements to accelerate veterinary product development and commercialization.
Structured Finance for Late-Stage (Phase III) Programs
Provides structured, non-dilutive financing solutions tailored to support Phase III and other late-stage clinical programs.
Royalty Monetization and Revenue-Interest Financings
Financing based on future royalties or revenue interests to provide non-dilutive capital to portfolio companies.
ESG Integration and Monitoring
An ESG Policy that integrates environmental, social and governance considerations into diligence, decision-making and portfolio monitoring where applicable.
PRODUCT FINANCE™ (late-stage product financing)
At-risk, non-dilutive financing designed to support late-stage product development and commercialization activities including pivotal trials, brand launches, licensing and asset acquisitions.
Animal Health Partnerships and Product Financing
Capital and expertise for animal health companies, including product financing agreements to accelerate veterinary product development and commercialization.
Structured Finance for Late-Stage (Phase III) Programs
Provides structured, non-dilutive financing solutions tailored to support Phase III and other late-stage clinical programs.
Royalty Monetization and Revenue-Interest Financings
Financing based on future royalties or revenue interests to provide non-dilutive capital to portfolio companies.
ESG Integration and Monitoring
An ESG Policy that integrates environmental, social and governance considerations into diligence, decision-making and portfolio monitoring where applicable.
Portfolio
$30 million product financing agreement to develop veterinary pharmaceuticals in partnership with Argenta.
#Animal Health
Launch included acquisition of Enzyvant’s investigational therapy for Farber disease and $35 million product financing with NovaQuest.
#Biopharma (rare disease)
Announced $70 million non-dilutive product finance transaction to support continued development and extend cash runway.
#Biopharma
Secured $35M Series C financing led by Mountain Group Partners and NovaQuest to commercialize a vaccine delivery system for poultry.
#Animal Health
Announced a revenue interest financing agreement for up to $260 million in non-dilutive capital.
#Biopharma
$30 million product financing agreement to develop veterinary pharmaceuticals in partnership with Argenta.
#Animal Health
Launch included acquisition of Enzyvant’s investigational therapy for Farber disease and $35 million product financing with NovaQuest.
#Biopharma (rare disease)
Announced $70 million non-dilutive product finance transaction to support continued development and extend cash runway.
#Biopharma
Secured $35M Series C financing led by Mountain Group Partners and NovaQuest to commercialize a vaccine delivery system for poultry.
#Animal Health
Announced a revenue interest financing agreement for up to $260 million in non-dilutive capital.
#Biopharma